BEZALIP SR 400 MG
BEZAFIBRATE : 400 MG · DIN 02083523 · ALLERGAN INC
Health Canada status: MARKETED
What is BEZALIP SR?
BEZALIP SR 400 MG contains BEZAFIBRATE : 400 MG. It is listed in the Health Canada Drug Product Database under DIN 02083523, held by ALLERGAN INC, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 03-Dec-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BEZALIP SR used for?
BEZALIP SR (bezafibrate) is indicated as an adjunct to diet and other therapeutic measures for: Treatment of patients with hypercholesterolemia Type IIa and IIb mixed hyperlipidemia, to regulate lipid and apoprotein levels (reduce serum TG, LDL cholesterol and apolipoprotein B, increase HDL cholesterol and apolipoprotein A). Treatment of adult patients with high to very high triglyceride levels, Fredrickson classification Type IV and V hyperlipidemias, who are at a high risk of sequelae and complications (i.e. pancreatitis) from their dyslipidemia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is BEZALIP SR called?
The same molecule, BEZAFIBRATE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Bezachole Sr | Latin | South Africa |
| Bezalip | Latin | South Africa |
| Bezalip Retard | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02083523 |
|---|---|
| Brand name | BEZALIP SR |
| Generic / active ingredient | BEZAFIBRATE : 400 MG |
| Manufacturer | ALLERGAN INC |
| Strength | 400 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C10AB02 BEZAFIBRATE |
| AHFS class | 24:06.06 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 03-Dec-2020 |
| Original market date | 1994-12-21 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02083523 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2083523 |
| Brand name | BEZALIP SR |
| Active ingredient / INN | BEZAFIBRATE : 400 MG |
| ATC code | C10AB02 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C10 |
| AHFS class | 24:06.06 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | ALLERGAN INC |
How is it administered?
One 400 mg sustained release tablet once daily, taken in the morning or evening with or after meals. Swallow whole without chewing.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at room temperature (15-30 °C). Protect from high humidity.
How is it supplied?
blister packs of 30
Which pack is which?
| Strength on the label | 400 MG |
|---|---|
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route | ORAL |
| Packaging as described in the monograph | blister packs of 30 |
| Storage | Store at room temperature (15-30 °C). Protect from high humidity. |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Contraindications
Hepatic/renal impairment, gallbladder disease, hypersensitivity to fibrates, photoallergic reactions, pregnancy/lactation, Type I hyperlipoproteinemia, combination with statins in high-risk patients.
Warnings and precautions
Risk of myositis/rhabdomyolysis (especially in renal impairment). Monitor liver function and blood counts. May lead to cholelithiasis. Discontinue if CPK >10x ULN or gallstones found.
What can be used instead?
Other Canadian products sharing ATC code C10AB02 BEZAFIBRATE. 2 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP-BEZAFIBRATE SR | 400 MG | Tablet | JAMP PHARMA CORPORATION | MARKETED | DIN 02453312 |
| ACT-BEZAFIBRATE SR | 400 MG | TABLET (EXTENDED-RELEASE) | ACTAVIS GROUP PTC EHF | CANCELLED PRE MARKET | DIN 02379414 |
| BEZALIP TAB 200MG | 200 MG | TABLET | HOFFMANN-LA ROCHE LIMITED | CANCELLED POST MARKET | DIN 02084082 |
| PMS-BEZAFIBRATE | 200 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02240331 |
Who else supplies BEZAFIBRATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BEZAFIBRATE appears in 12 registered pack listings across 5 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does BEZAFIBRATE cost around the world?
BEZAFIBRATE is listed on 4 national price registers Nexara tracks, across 10 pack listings published on 3 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| South Africa | single exit price | 5 | 5 | 01 Sep 2026 |
| United Kingdom | hospital | 2 | 2 | 31 Aug 2026 |
| Saudi Arabia | public | 2 | 2 | 01 Sep 2026 |
| United Arab Emirates | public | 1 | 1 | 31 Aug 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.